Literature DB >> 5457513

Myasthenia gravis and the myasthenic syndrome.

C Herrmann.   

Abstract

Two disorders of neuromuscular transmission producing muscle weakness and easy fatigability which may confront the physician are myasthenia gravis and the myasthenic syndrome. The former has early symptoms and signs of oculobulbar and then extremity weakness with rapid decline of action potential and contractile strength with repetitive use and nerve-muscle stimulation. Anticholinesterases improve strength. The myasthenic syndrome has early symptoms and signs of pelvic girdle, pectoral girdle and proximal limb muscle weakness. This is worst when first starting to use or carry out nerve muscle stimulation in the rested muscles. It improves significantly for a time with use or on rapid stimulation, and then declines with continued activation. Deep tendon reflexes are sluggish or absent. Small cell carcinoma of the lung is often associated. Guanidine improves the strength. Other features and possible underlying mechanisms of the two disorders help to differentiate and treat them.

Entities:  

Mesh:

Year:  1970        PMID: 5457513      PMCID: PMC1501575     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  42 in total

1.  Histological changes in the striped muscles in myasthenia gravis.

Authors:  D S RUSSELL
Journal:  J Pathol Bacteriol       Date:  1953-04

2.  Does myasthenic serum bind to the neuromuscular junction?

Authors:  D E McFarlin; W K Engel; A J Strauss
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

3.  Further studies on the specificity of presumed immune associations of myasthenia gravis and consideration of possible pathogenic implications.

Authors:  A J Strauss; C W Smith; G W Cage; H W van der Geld; D E McFarlin; M Barlow
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

4.  Muscle antibodies in myasthenic mothers and their babies.

Authors:  H J Oosterhuis; T E Feltkamp; H R van der Geld
Journal:  Lancet       Date:  1966-12-03       Impact factor: 79.321

5.  Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma.

Authors:  D Elmqvist; E H Lambert
Journal:  Mayo Clin Proc       Date:  1968-10       Impact factor: 7.616

6.  Antigens in thymus and muscle effective in inducing experimental autoimmune thymitis and the release of thymin.

Authors:  G Goldstein; A J Strauss; S Pickeral
Journal:  Clin Exp Immunol       Date:  1969-01       Impact factor: 4.330

7.  Acetylcholine utulization in myasthenia gravis.

Authors:  S Thesleff
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

8.  Reappraisal of in vitro muscle biopsy in myasthenia gravis.

Authors:  C Herrmann; P B Sabawala; W F Barker; J B Dillon
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

9.  Myasthenia gravis occurring in families.

Authors:  C Herrmann
Journal:  Neurology       Date:  1966-01       Impact factor: 9.910

10.  Treatment of myasthenia gravis with adrenocorticotropic hormone (ACTH): massive short-term and maintenance treatment.

Authors:  C A Cape; R A Utterback
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-08       Impact factor: 10.154

View more
  1 in total

1.  Myasthenia gravis after 300 years: continued search.

Authors:  C Herrmann
Journal:  Calif Med       Date:  1973-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.